Altimmune, Inc.
ALT· Nasdaq
Released Nov 12, 2024, before the open
10-Q filed Nov 12, 2024, 43 days after period end · 0001326190-24-000050
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $5.00K | $362.00K | $2.00K | $158.00K |
| Net Income | -$22.85M | -$20.67M | -$23.52M | -$33.51M |
| EPS Diluted |
Altimmune, Inc. · CIK 1326190 · Engraved from SEC EDGAR
| -$0.32 |
| -$0.39 |
| -$0.48 |
| -$0.81 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.